GNCA Stock
GNCA Stock

Bellerophon Therapeutics, Inc. (BLPH) stock surged 30.38% in the current-market trading session at the price of $3.09 after reporting positive top-line data from the Phase-II dose-escalation study of INOpulse.

Bellerophon Therapeutics is a clinical-stage biotherapeutics firm. It develops innovative therapies to address the unmet medical needs of patients with cardiopulmonary diseases. 

Positive Top-Line Data from Phase-II Study of INOpulse 

On 17th December 2021, BLPH reported positive top-line data from the Phase-II dose-escalation study of INOpulse. PULSE-PHPF-002 study evaluates the acute hemodynamic benefit of INOpulse to treat pulmonary hypertension associated with sarcoidosis. 

Management Comments  

Principal Investigators of PULSE-PHPF-002, Robert Baughman, remarked that pulmonary hypertension-related sarcoidosis has a median survival of five years after the growth of pulmonary hypertension. They are motivated by the positive results observed in patients with pulmonary hypertension acutely treated with INOpulse. The study remained well tolerated with no decline in pulmonary capillary wedge pressure. The results from this study support evaluation of the potential of iNO for the treatment of PH-Sarc patients, he added.  

BLPH Third Quarter 2021 Financial Results 

On 15th November 2021, BLPH published its financial results for the third quarter ended 30th September 2021. The company has also presented its clinical program updates.   

Q3 2021 Financial Highlights 

For the Q3 ended 30th September 2021, BLPH calculated an operating loss of roughly $4.8 million. Operating loss was $8.3 million for the same three months of 2020. The net loss was $4.6 million, or per basic and diluted share of $(0.49), for the third quarter of 2021. For the third quarter of 2020, net loss was $7.9 million, or per basic and diluted share of $(0.84). Research and development expenses were $3.0 million for the Q3 ended 30th September 2021. For the third quarter of 2021, general and administrative costs were $1.8 million. 

BLPH Nine Months Financial Results 

For the nine months ended 30th September 2021, BLPH reported a net loss of $13.5 million, or per basic and diluted share of $(1.42). The net loss was $16.7 million, or per basic and diluted share of $(2.31), for the nine months ended 30th September 2020.

LEAVE A REPLY

Please enter your comment!
Please enter your name here